NICE Rejects BMS' Opdivo As Adult Kidney Cancer Treatment
The UK HTA NICE in draft guidance has rejected Bristol-Myers Squibb Co.'s Opdivo (nivolumab) as a therapy for previously treated advanced renal cell carcinoma in adults, saying the PD-1 inhibitor doesn't offer value for money. It added that it should also not be made available to such patients through the government-funded Cancer Drugs Fund, for the same reasons.
You may also be interested in...
BMS looks unlikely to have a positive NICE opinion synchronized with European approval of Opdivo in head and neck cancer, after the HTA body turned down the checkpoint inhibitor in its draft appraisal.
Bristol-Myers Squibb's Opdivo looks set to blow rivals out the water in renal cell carcinoma as NICE U-turns on negative recommendation, just weeks after the company revealed the full extent of the drug’s disappointment in first-line lung cancer.
The UK HTA has recommended Bristol-Myers Squibb's combination therapy of Opdivo and Yervoy to treat patients on the publicly-funded NHS with advanced skin cancer, marking one of the quickest decisions ever from NICE and issued only weeks after the combo was licensed by the EU's European Commission.